PriceTargets.com logo

Aurinia Pharmaceuticals - AUP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00 As of 07/31/2021 12:59 AM ET
+0 (0.00%)

This chart shows the closing price for AUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUP

Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for AUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Aurinia Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/6/2021Royal Bank of CanadaReiterated RatingOutperformC$23.00
6/28/2021Royal Bank of CanadaReiterated RatingOutperformC$28.00
5/21/2021Royal Bank of CanadaReiterated RatingOutperformC$28.00
5/7/2021Bloom BurtonUpgradeAccumulate ➝ Buy
5/7/2021Royal Bank of CanadaLower TargetOutperformC$28.00
4/29/2021Royal Bank of CanadaReiterated RatingOutperformC$32.00
11/3/2020Bloom BurtonDowngradeBuy ➝ Accumulate
10/17/2019Cantor FitzgeraldReiterated RatingOverweight
10/2/2019Bloom BurtonReiterated RatingBuy
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: C$16.76
Low: C$16.76
High: C$16.76

52 Week Range

Now: N/A

Volume

4,611,683 shs

Average Volume

229,895 shs

Market Capitalization

C$2.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Aurinia Pharmaceuticals in the last twelve months:
View the latest analyst ratings for AUP.

What is the current price target for Aurinia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUP.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AUP.

What other companies compete with Aurinia Pharmaceuticals?

Other companies that are similar to Aurinia Pharmaceuticals include Absolute Software Co. (ABT.TO), LifeWorks, BlackBerry, Docebo and Mitel Networks. Learn More about companies similar to Aurinia Pharmaceuticals.

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company's listed phone number is +1-250-7084272. The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. Learn More about contacing Aurinia Pharmaceuticals investor relations.